F-18-FDG and C-11-choline positron emission tomography in human esophago-gastric cancer

prediction of response to therapy

Stuart Suttie, Dympna McAteer, Margaret Sheehan, Marianne Nicolson, Lutz Schweiger, Solveig Hammonds, Timothy Smith, Andrew Welch, Kenneth Park

Research output: Contribution to journalArticle

4 Downloads (Pure)

Abstract

Background: To determine the utility of F-18-FDG and C-11-Choline uptake, in patients with esophageal and esophago-gastric junction tumors who are to undergo either neo-adjuvant or palliative chemotherapy, in predicting response (pathological and survival).

Methods: Eighteen patients with biopsy proven cancer were recruited prospectively. Patients underwent PET imaging before and during the first cycle of chemotherapy (seven and 14 days) with both F-18-FDG and C-11-Choline. Tracer uptake was quantified using Standardized Uptake Values. Pathological tumor response was determined using the Mandard criteria. Cellular proliferation was determined using ki-67 immunohistochemistry. Relationships between tracer uptake and response, one-year survival and cellular proliferation were determined.

Results: All 18 tumors were imaged by F-18-FDG PET compared to 16/18 with C-11-Choline. Change in uptake of either tracer did not correlate with pathological response. Pathological response did not influence survival (median-survival, responders = 16.1 months; non-responders = 19.0 months, p = 0.978). There was no significant correlation of change in tracer uptake with survival. C-11-Choline tumor uptake did not correlate with cellular proliferation.

Conclusion: F-18-FDG PET is superior for imaging of the primary tumor. Neither F-18-FDG nor C-11-Choline PET was able to predict response accurately.
Original languageEnglish
Pages (from-to)66-77
Number of pages12
JournalWorld Journal of Oncology
Volume1
Issue number2
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Choline
Positron-Emission Tomography
Stomach Neoplasms
Survival
Neoplasms
Cell Proliferation
Therapeutics
Drug Therapy
Stomach
Immunohistochemistry
Biopsy

Keywords

  • positron emission tomography
  • esophageal cancer
  • F-18-FDG
  • C-11-choline
  • response

Cite this

F-18-FDG and C-11-choline positron emission tomography in human esophago-gastric cancer : prediction of response to therapy. / Suttie, Stuart; McAteer, Dympna; Sheehan, Margaret; Nicolson, Marianne; Schweiger, Lutz; Hammonds, Solveig; Smith, Timothy; Welch, Andrew; Park, Kenneth.

In: World Journal of Oncology, Vol. 1, No. 2, 04.2010, p. 66-77.

Research output: Contribution to journalArticle

Suttie, Stuart ; McAteer, Dympna ; Sheehan, Margaret ; Nicolson, Marianne ; Schweiger, Lutz ; Hammonds, Solveig ; Smith, Timothy ; Welch, Andrew ; Park, Kenneth. / F-18-FDG and C-11-choline positron emission tomography in human esophago-gastric cancer : prediction of response to therapy. In: World Journal of Oncology. 2010 ; Vol. 1, No. 2. pp. 66-77.
@article{3a6c78f2d3ad45dc841a50dd2f216cfc,
title = "F-18-FDG and C-11-choline positron emission tomography in human esophago-gastric cancer: prediction of response to therapy",
abstract = "Background: To determine the utility of F-18-FDG and C-11-Choline uptake, in patients with esophageal and esophago-gastric junction tumors who are to undergo either neo-adjuvant or palliative chemotherapy, in predicting response (pathological and survival). Methods: Eighteen patients with biopsy proven cancer were recruited prospectively. Patients underwent PET imaging before and during the first cycle of chemotherapy (seven and 14 days) with both F-18-FDG and C-11-Choline. Tracer uptake was quantified using Standardized Uptake Values. Pathological tumor response was determined using the Mandard criteria. Cellular proliferation was determined using ki-67 immunohistochemistry. Relationships between tracer uptake and response, one-year survival and cellular proliferation were determined. Results: All 18 tumors were imaged by F-18-FDG PET compared to 16/18 with C-11-Choline. Change in uptake of either tracer did not correlate with pathological response. Pathological response did not influence survival (median-survival, responders = 16.1 months; non-responders = 19.0 months, p = 0.978). There was no significant correlation of change in tracer uptake with survival. C-11-Choline tumor uptake did not correlate with cellular proliferation. Conclusion: F-18-FDG PET is superior for imaging of the primary tumor. Neither F-18-FDG nor C-11-Choline PET was able to predict response accurately.",
keywords = "positron emission tomography, esophageal cancer, F-18-FDG, C-11-choline, response",
author = "Stuart Suttie and Dympna McAteer and Margaret Sheehan and Marianne Nicolson and Lutz Schweiger and Solveig Hammonds and Timothy Smith and Andrew Welch and Kenneth Park",
year = "2010",
month = "4",
doi = "10.4021/wjon2010.04.201w",
language = "English",
volume = "1",
pages = "66--77",
journal = "World Journal of Oncology",
issn = "1920-4531",
publisher = "Elmer Press Inc",
number = "2",

}

TY - JOUR

T1 - F-18-FDG and C-11-choline positron emission tomography in human esophago-gastric cancer

T2 - prediction of response to therapy

AU - Suttie, Stuart

AU - McAteer, Dympna

AU - Sheehan, Margaret

AU - Nicolson, Marianne

AU - Schweiger, Lutz

AU - Hammonds, Solveig

AU - Smith, Timothy

AU - Welch, Andrew

AU - Park, Kenneth

PY - 2010/4

Y1 - 2010/4

N2 - Background: To determine the utility of F-18-FDG and C-11-Choline uptake, in patients with esophageal and esophago-gastric junction tumors who are to undergo either neo-adjuvant or palliative chemotherapy, in predicting response (pathological and survival). Methods: Eighteen patients with biopsy proven cancer were recruited prospectively. Patients underwent PET imaging before and during the first cycle of chemotherapy (seven and 14 days) with both F-18-FDG and C-11-Choline. Tracer uptake was quantified using Standardized Uptake Values. Pathological tumor response was determined using the Mandard criteria. Cellular proliferation was determined using ki-67 immunohistochemistry. Relationships between tracer uptake and response, one-year survival and cellular proliferation were determined. Results: All 18 tumors were imaged by F-18-FDG PET compared to 16/18 with C-11-Choline. Change in uptake of either tracer did not correlate with pathological response. Pathological response did not influence survival (median-survival, responders = 16.1 months; non-responders = 19.0 months, p = 0.978). There was no significant correlation of change in tracer uptake with survival. C-11-Choline tumor uptake did not correlate with cellular proliferation. Conclusion: F-18-FDG PET is superior for imaging of the primary tumor. Neither F-18-FDG nor C-11-Choline PET was able to predict response accurately.

AB - Background: To determine the utility of F-18-FDG and C-11-Choline uptake, in patients with esophageal and esophago-gastric junction tumors who are to undergo either neo-adjuvant or palliative chemotherapy, in predicting response (pathological and survival). Methods: Eighteen patients with biopsy proven cancer were recruited prospectively. Patients underwent PET imaging before and during the first cycle of chemotherapy (seven and 14 days) with both F-18-FDG and C-11-Choline. Tracer uptake was quantified using Standardized Uptake Values. Pathological tumor response was determined using the Mandard criteria. Cellular proliferation was determined using ki-67 immunohistochemistry. Relationships between tracer uptake and response, one-year survival and cellular proliferation were determined. Results: All 18 tumors were imaged by F-18-FDG PET compared to 16/18 with C-11-Choline. Change in uptake of either tracer did not correlate with pathological response. Pathological response did not influence survival (median-survival, responders = 16.1 months; non-responders = 19.0 months, p = 0.978). There was no significant correlation of change in tracer uptake with survival. C-11-Choline tumor uptake did not correlate with cellular proliferation. Conclusion: F-18-FDG PET is superior for imaging of the primary tumor. Neither F-18-FDG nor C-11-Choline PET was able to predict response accurately.

KW - positron emission tomography

KW - esophageal cancer

KW - F-18-FDG

KW - C-11-choline

KW - response

U2 - 10.4021/wjon2010.04.201w

DO - 10.4021/wjon2010.04.201w

M3 - Article

VL - 1

SP - 66

EP - 77

JO - World Journal of Oncology

JF - World Journal of Oncology

SN - 1920-4531

IS - 2

ER -